Guidelines for the medical treatment of idiopathic pulmonary fibrosis

Arch Bronconeumol. 2017 May;53(5):263-269. doi: 10.1016/j.arbres.2016.12.011. Epub 2017 Mar 11.
[Article in English, Spanish]

Abstract

Idiopathic pulmonary fibrosis is defined as chronic fibrosing interstitial pneumonia limited to the lung, with poor prognosis. The incidence has been rising in recent years probably due to improved diagnostic methods and increased life expectancy. In 2013, the SEPAR guidelines for the diagnosis and treatment for idiopathic pulmonary fibrosis were published. Since then, clinical trials and meta-analyses have shown strong scientific evidence for the use of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis. In 2015, the international consensus of 2011 was updated and new therapeutic recommendations were established, prompting us to update our recommendation for the medical treatment of idiopathic pulmonary fibrosis accordingly. Diagnostic aspects and non-pharmacological treatment will not be discussed as no relevant developments have emerged since the 2013 guidelines.

Keywords: Fibrosis pulmonar idiopática; Idiopathic pulmonary fibrosis; Nintedanib; Pirfenidona; Pirfenidone; Tratamiento; Treatment.

Publication types

  • Practice Guideline

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Disease Progression
  • Disease-Free Survival
  • Evidence-Based Medicine
  • Gastroesophageal Reflux / complications
  • Gastroesophageal Reflux / therapy
  • Gastrointestinal Diseases / chemically induced
  • Humans
  • Hypertension, Pulmonary / complications
  • Idiopathic Pulmonary Fibrosis / complications
  • Idiopathic Pulmonary Fibrosis / drug therapy*
  • Indoles / adverse effects
  • Indoles / therapeutic use
  • Meta-Analysis as Topic
  • Pulmonary Emphysema / complications
  • Pyridones / adverse effects
  • Pyridones / therapeutic use
  • Randomized Controlled Trials as Topic
  • Societies, Medical / standards
  • Spain

Substances

  • Adrenal Cortex Hormones
  • Indoles
  • Pyridones
  • pirfenidone
  • nintedanib